You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The sequencing firm is offering 19.4 million shares of common stock at $4.47 per share and plans to use the proceeds for product launches, among other uses.
The sequencing firm said the COVID-19 pandemic had a negative impact on revenues, which totaled $17.1 million, down from $24.6 million in the prior-year period.
Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.
In Science this week: Fiber-seq method to examine regulatory architecture, mutations in SOST associated with osteoporosis drug-linked cardiovascular events, and more.
Taiwan-based Personal Genomics, which is developing a new single-molecule sequencing platform, has previously sued PacBio for patent infringement in the US.
The sequencing firm reported total revenues of $15.6 million, with instrument revenue negatively impacted by shutdowns precipitated by COVID-19.
In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.
The Delaware jury said Oxford Nanopore had infringed three patents, but also found that they were invalid, mostly because they were not enabled.
The methods exploit a feature of Oxford Nanopore's technology that ejects molecules mid-read, enabling a new level of control over human DNA sequencing runs.
All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.